跳至主要内容
临床试验/JPRN-UMIN000012817
JPRN-UMIN000012817招募中2 期

Randomized controlled trial for peripheral neuropathy comparing weekly Paclitaxel followed by FEC100 with Eribulin Mesilate followed by FEC100 as neoadjuvant chemotherapy in primary breast cancer patients. - JONIE 3 Study

JONIE Study Group0 个研究点目标入组 230 人开始时间: 2014年1月11日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
230

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • (1)Non-invasive breast cancer and Invasive micropapillary carcinoma (2)Inflammatory breast caner (3) Bilateral breast cancer(synchronous or asynchrous) (4) No prior chemotherapy, endocrine therapy and radiotherapy for breast cancer (5) Active double cancer (6) Patients with myocardial infarction or congestive heart failure at the past history, or patients who need treatment of ischemic hear disease, arryhythmia or valvular disorder. (7) Severe complication (infectious diseases, interstitial pneumonia peripheral neuropathy, uncontrolled diabetes, bleeding tendency) (8) Those who are pregnant, potentially pregnant or breast-feeding (9) Those known to have active Hepatitis B or C Viral Infection (HBs(+) or HCV(+)) (10)Patients who have an allergy for alcohol (11) Patient judged inappropriate for this study by the physicians

研究者

发起方
JONIE Study Group

相似试验